We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-8.19%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$417M
AUM Growth
+$3.18M
Cap. Flow
+$36.7M
Cap. Flow %
8.81%
Top 10 Hldgs %
53.86%
Holding
43
New
13
Increased
11
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$17.1M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$14.3M
3
NKTR icon
Nektar Therapeutics
NKTR
+$13.2M
4
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$11.3M
5
DTIL icon
Precision BioSciences
DTIL
+$11.3M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$29.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$24.2M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$22.2M
4
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$17.1M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 93.09%
2 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
1
Xenon Pharmaceuticals
XENE
$6.06B
$33.6M 8.06%
1,104,334
+184,334
+20% +$5.57M
JAZZ icon
2
Jazz Pharmaceuticals
JAZZ
$15.9B
$29.6M 7.11%
190,000
+35,000
+23% +$5.39M
CYTK icon
3
Cytokinetics
CYTK
$10.5B
$24M 5.75%
610,000
-40,000
-6% -$1.61M
TVTX icon
4
Travere Therapeutics
TVTX
$5.2B
$23.5M 5.64%
971,233
-38,767
-4% -$975K
ALNY icon
5
PUT
Alnylam Pharmaceuticals
ALNY
$27.5B
$21.9M 5.25%
+150,000
New +$21.3M
PCVX icon
6
Vaxcyte
PCVX
$7.81B
$21.4M 5.14%
985,153
+100,000
+11% +$2.31M
LKFT
7
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$20.1M 4.82%
360,000
– –
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$18.9M 4.52%
+149,000
New +$17.1M
PNT
9
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$16.5M 3.95%
2,420,501
+360,501
+18% +$2.76M
ACRS icon
10
Aclaris Therapeutics
ACRS
$726M
$15.1M 3.63%
1,083,000
+140,555
+15% +$1.97M
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$15.1M 3.61%
1,530,000
+655,803
+75% +$7.23M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.57B
$14.5M 3.49%
+193,900
New +$14.3M
RLMD icon
13
Relmada Therapeutics
RLMD
$557M
$13.3M 3.19%
700,000
-90,000
-11% -$1.96M
CINC
14
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$12.6M 3.02%
669,200
+589,530
+740% +$11.3M
NKTR icon
15
Nektar Therapeutics
NKTR
$2.39B
$12M 2.87%
+210,000
New +$13.2M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$5.8B
$11.7M 2.8%
1,204,028
+85,961
+8% +$802K
TCDA
17
DELISTED
Tricida, Inc. Common Stock
TCDA
$11.3M 2.7%
1,164,763
-85,237
-7% -$811K
ALKS icon
18
Alkermes
ALKS
$8.22B
$10.8M 2.58%
+361,636
New +$10.4M
DTIL icon
19
Precision BioSciences
DTIL
$180M
$9.21M 2.21%
+191,847
New +$11.3M
ANAB icon
20
AnaptysBio
ANAB
$1.58B
$9.2M 2.21%
453,118
-246,882
-35% -$5.47M
NBIX icon
21
Neurocrine Biosciences
NBIX
$16.8B
$7.31M 1.75%
+75,000
New +$6.92M
RNAM
22
DELISTED
Avidity Biosciences
RNAM
$7.26M 1.74%
500,000
– –
URGN icon
23
UroGen Pharma
URGN
$1.86B
$7.15M 1.72%
873,424
– –
ABOS icon
24
Acumen Pharmaceuticals
ABOS
$155M
$7.12M 1.71%
1,515,000
+586,718
+63% +$2.2M
KRTX
25
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.95M 1.67%
+54,900
New +$6.31M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Great Point Partners held 43 positions worth $417M, up 0.77% from $414M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners deployed $36.7M of net new capital in Q2 2022, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Karuna Therapeutics, Inc. Common Stock: 149,000 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Chinook Therapeutics, Inc. Common Stock, an estimated $17.1M trimmed.

  • Great Point Partners's largest Q2 2022 buy was Karuna Therapeutics, Inc. Common Stock: 149,000 shares worth $18.9M.
  • Great Point Partners added most to CinCor Pharma, Inc. Common Stock in Q2 2022, an estimated $11.3M increase.
  • Great Point Partners's biggest Q2 2022 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $17.1M.
  • Great Point Partners fully exited Exelixis in Q2 2022, selling an estimated $29.5M.
  • Great Point Partners's ten largest holdings make up 54% of its $417M portfolio in Q2 2022.
  • Great Point Partners opened 13 new positions and closed 8 in Q2 2022.
  • Great Point Partners's portfolio value rose 0.77% quarter-over-quarter to $417M.

Based on Great Point Partners's 13F filing for Q2 2022, filed 15 Aug 2022.